Evicenter
P&T meetings

Bezuclastinib

Gastrointestinal stromal tumor

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted April 2026
Last updated
76 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of other drugs on Bezuclastinib

2 evidence topics · 2 sources

Sunitinib combination pharmacokinetics

“Combination with sunitinib did not have an impact on PK of bezuclastinib” (opens the source at this quote in a new tab)

PEAK exclusion criterion: CYP3A4 modifiers

“Received strong CYP3A4 inhibitors or inducers” (opens the source at this quote in a new tab)